ENDOLEASE
Targeted Drug Delivery
The worldwide first intra-arterial drug releasing system boosts efficacy and minimizes side effects.
Common methods of drug administration include oral ingestion or intravenous injection, which results in systemic effects on the body.
Unfortunately, the adverse reactions often outbalance the therapeutic use and lead to dose-limiting side effects (e.g. chemotherapeutics).
Systemic drug administration is the crucial dilemma in Pharmacology!
Status Quo
The ENDOLEASE
Disruptive Innovation
- A patented tubular implant which is based on biodegradable FDA approved materials and positioned into an artery.
- ENDOvascular reLEASE of drugs into bloodstream and hence increasing efficacy although minimizing adverse reactions.
- Paving the way for drugs limited by systemic side effects.
Various Applications
The ENDOLEASE-System can Implanted by a minimally invasive catheter in almost any artery targeting specific tissues. This allows a wide range of applications.
In particular, drugs which failed in clinical studies due to side effects or are limited by those, profit from the ENDOLEASE-System.
Myocardial Infarction
Cardio-protective drugs such as Fingolimod can not be administered systemically after infarction. The ENDOLEASE-System releases the agents directly to the targeted tissue to stop inflammatory remodelling processes without systemic immunosuppression.
Stroke
After a stroke patients often suffer from oedema with subsequent increasing intracranial pressure. Glucocorticoids with Bortezomib would prevent this mechanism but are not applicable due to systemic side effects. Treating with the ENDOLEASE-System protects from the described vicious circle.
Cancer
The dose of chemotherapeutics is limited by severe side effects. An example is the treatment of breast cancer with Doxorubicin and cardiotoxicity as a side effect. The ENDOLEASE-System allows treating solid tumours with higher doses and minimal adverse reactions.
About Us
As Spin-off from University Hospital Würzburg we are looking for funding to prove our patented Endolease technology by in vivo studies.
"We are a highly interdisciplinary team with intrinsic motivation
to offer patients new therapies with a revolutionary drug administration."
Anna Fleischer, MD
Medical Doctor at UKW focusing on clinical development
Tomasz Jüngst, PhD
Professor for Biofabrication technologies at UKW
Heinz Schwer, PhD
Entrepreneur with +20 years of experience in startup management
Johannes Braig
PhD candidate and MD student at UKW focusing on medical validation
Michael Bartolf-Kopp
PhD candidate at UKW focusing on scaffold fabrication
Franz Moser
PhD candidate at UKW focusing on material optimization
Catherine Schreiber
Entrepreneur and formerly founder of ADVITOS
Contact Us
Email:
Info@endolease.de
A Spin-off Initiative from:
Department for Functional Materials
Pleicherwall 2
97070 Würzburg
2024 © ENDOLEASE – Imprint – Privacy Policy